Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017, Article ID 4541958, 8 pages
https://doi.org/10.1155/2017/4541958
Review Article

Sildenafil Can Affect Innate and Adaptive Immune System in Both Experimental Animals and Patients

Department of Clinical Immunology, Institute of Transplantology, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warsaw, Poland

Correspondence should be addressed to Monika Kniotek; lp.pw@ketoinkm

Received 17 September 2016; Revised 20 November 2016; Accepted 20 December 2016; Published 20 February 2017

Academic Editor: Eyad Elkord

Copyright © 2017 Monika Kniotek and Agnieszka Boguska. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Lugnier, “Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents,” Pharmacology and Therapeutics, vol. 109, no. 3, pp. 366–398, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. G. L. Card, B. P. England, Y. Suzuki et al., “Structural basis for the activity of drugs that inhibit phosphodiesterases,” Structure, vol. 12, no. 12, pp. 2233–2247, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Conti and S. L. Jin, “The molecular biology of cyclic nucleotide phosphodiesterases,” Progress in Nucleic Acid Research and Molecular Biology, vol. 63, pp. 1–38, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. W. J. Thompson, “Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function,” Pharmacology and Therapeutics, vol. 51, no. 1, pp. 13–33, 1991. View at Publisher · View at Google Scholar · View at Scopus
  5. D. M. Essayan, “Cyclic nucleotide phosphodiesterases,” Journal of Allergy and Clinical Immunology, vol. 108, no. 5, pp. 671–680, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. H. Jeon, Y. S. Heo, C. M. Kim et al., “Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development,” Cellular and Molecular Life Sciences, vol. 62, no. 11, pp. 1198–1220, 2005. View at Google Scholar
  7. D. M. G. Halpin, “ABCD of the phosphodiesterase family: interaction and differential activity in COPD,” International Journal of COPD, vol. 3, no. 4, pp. 543–561, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. J. D. Corbin and S. H. Francis, “Cyclic GMP phosphodiesterase-5: target of sildenafil,” Journal of Biological Chemistry, vol. 274, no. 20, pp. 13729–13732, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. M. D. Houslay and D. R. Adams, “PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization,” Biochemical Journal, vol. 370, no. 1, pp. 1–18, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. W. K. Sonnenburg, D. Seger, K. S. Kwak, J. Huang, H. Charbonneau, and J. A. Beavo, “Identification of inhibitory and calmodulin-binding domains of the PDE1A1 and PDE1A2 calmodulin-stimulated cyclic nucleotide phosphodiesterases,” The Journal of Biological Chemistry, vol. 270, no. 52, pp. 30989–31000, 1995. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Zoraghi, J. D. Corbin, and S. H. Francis, “Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity,” Journal of Biological Chemistry, vol. 281, no. 9, pp. 5553–5558, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. S. H. Francis, T. M. Lincoln, and J. D. Corbin, “Characterization of a novel cGMP binding protein from rat lung,” Journal of Biological Chemistry, vol. 255, no. 2, pp. 620–626, 1980. View at Google Scholar · View at Scopus
  13. W. B. Smith, I. R. McCaslin, A. Gokce, S. H. Mandava, L. Trost, and W. J. Hellstrom, “PDE5 inhibitors: considerations for preference and long-term adherence,” International Journal of Clinical Practice, vol. 67, no. 8, pp. 768–780, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Domek-Łopacińska and J. B. Strosznajder, “Cyclic GMP metabolism and its role in brain physiology,” Journal of Physiology and Pharmacology, vol. 56, no. 2, pp. 15–34, 2005. View at Google Scholar · View at Scopus
  15. R. C. Kukreja, F. Salloum, A. Das et al., “Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications,” Vascular Pharmacology, vol. 42, no. 5-6, pp. 219–232, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Kobayashi, “The regulatory role of nitric oxide in proinflammatory cytokine expression during the induction and resolution of inflammation,” Journal of Leukocyte Biology, vol. 88, no. 6, pp. 1157–1162, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. X.-M. Liu, K. J. Peyton, X. Wang, and W. Durante, “Sildenafil stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells via distinct signaling pathways,” Biochemical Pharmacology, vol. 84, no. 8, pp. 1045–1054, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Bełtowski, A. Jamroz, and E. Borkowska, “Heme oxygenase and carbon monoxide in the physiology and pathology of the cardiovascular system,” Postpy higieny i medycyny doświadczalnej (Online), vol. 58, pp. 83–99, 2004. View at Google Scholar · View at Scopus
  19. V. Krajka-Kuźniak, “Indukcja enzymów II fazy jako strategia chemioprewencji nowotworów i innych schorzeń degeneracyjnych,” Potsępy Higieny i Medycyny Doświadczalnej, vol. 61, pp. 627–638, 2007. View at Google Scholar
  20. A. K. de Santana Nunes, C. Rapôso, U. Björklund, M. A. da Cruz-Höfling, C. A. Peixoto, and E. Hansson, “Sildenafil (Viagra(®)) prevents and restores LPS-induced inflammation in astrocytes,” Neuroscience Letters, vol. 630, pp. 59–65, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Karakhanova, Y. Yang, J. Link et al., “Gender-specific immunological effects of the phosphodiesterase 5 inhibitor sildenafil in healthy mice,” Molecular Immunology, vol. 56, no. 4, pp. 649–659, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. S. L. Klein, “Immune cells have sex and so should journal articles,” Endocrinology, vol. 153, no. 6, pp. 2544–2550, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Szczypka and B. Obmińska-Mrukowicz, “Modulating effects of nonselective and selective phosphodiesterase inhibitors on lymphocyte subsets and humoral immune response in mice,” Pharmacological Reports, vol. 62, no. 6, pp. 1148–1158, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Szczypka, S. Ploch, and B. Obmińska-Mrukowicz, “Modulation of Th1/Th2 cytokine production by selective and nonselective phosphodiesterase inhibitors administered to mice,” Pharmacological Reports, vol. 64, no. 1, pp. 179–184, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Szczypka and B. Obmiska-Mrukowicz, “The effects of selective and nonselective phosphodiesterase inhibitors on phagocytic cells in mice,” Immunopharmacology and Immunotoxicology, vol. 32, no. 3, pp. 507–513, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. A. T. Bender and J. A. Beavo, “Specific localized expression of cGMP PDEs in Purkinje neurons and macrophages,” Neurochemistry International, vol. 45, no. 6, pp. 853–857, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. M. A. Friese, X. Montalban, N. Willcox, J. I. Bell, R. Martin, and L. Fugger, “The value of animal models for drug development in multiple sclerosis,” Brain, vol. 129, no. 8, pp. 1940–1952, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. B. D. Trapp and K.-A. Nave, “Multiple sclerosis: an immune or neurodegenerative disorder?” Annual Review of Neuroscience, vol. 31, pp. 247–269, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Prado, M. A. Baltrons, P. Pifarré, and A. García, “Glial cells as sources and targets of natriuretic peptides,” Neurochemistry International, vol. 57, no. 4, pp. 367–374, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Pifarré, M. Gutierrez-Mecinas, J. Prado et al., “Phosphodiesterase 5 inhibition at disease onset prevents experimental autoimmune encephalomyelitis progression through immunoregulatory and neuroprotective actions,” Experimental Neurology, vol. 251, pp. 58–71, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Pifarre, J. Prado, M. A. Baltrons et al., “Sildenafil (Viagra) ameliorates clinical symptoms and neuropathology in a mouse model of multiple sclerosis,” Acta Neuropathologica, vol. 121, no. 4, pp. 499–508, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. A. K. S. Nunes, A. Raposo, L. C. Almeida et al., “Sildenafil (Viagra) down regulates cytokines and prevents demyelination in a cuprizone-indiced MS mouse model,” Cytokine, vol. 60, pp. 540–551, 2012. View at Google Scholar
  33. A. K. S. Nunes, C. Rapôso, S. W. S. Rocha et al., “Involvement of AMPK, IKβα-NFκB and eNOS in the sildenafil anti-inflammatory mechanism in a demyelination model,” Brain Research, vol. 1627, pp. 119–133, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. R. L. Luna, A. K. S. Nunes, A. G. V. Oliveira et al., “Sildenafil (Viagra®) blocks inflammatory injury in LPS-induced mouse abortion: a potential prophylactic treatment against acute pregnancy loss?” Placenta, vol. 36, no. 10, pp. 1122–1129, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. R. L. Luna, A. G. Vasconcelos, A. K. Santana Nunes, W. H. De Oliveira, K. P. De Sousa Barbosa, and C. A. Peixoto, “Effects of sildenafil citrate and heparin treatments on placental cell morphology in a murine model of pregnancy loss,” Cells Tissues Organs, vol. 201, no. 3, pp. 193–202, 2016. View at Publisher · View at Google Scholar · View at Scopus
  36. P. M. Bosio, S. Cannon, P. J. McKenna, C. O'Herlihy, R. Conroy, and H. Brady, “Plasma P-selectin is elevated in the first trimester in women who subsequently develop pre-eclampsia,” British Journal of Obstetrics and Gynaecology, vol. 108, no. 7, pp. 709–715, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. V. A. Holmes, J. M. W. Wallace, W. S. Gilmore, P. McFaul, and H. D. Alexander, “Soluble P-selectin levels during normal pregnancy: a longitudinal study,” BJOG, vol. 109, no. 9, pp. 997–1002, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Serafini, K. Meckel, M. Kelso et al., “Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function,” Journal of Experimental Medicine, vol. 203, no. 12, pp. 2691–2702, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Meyera, A. Sevko, M. Ramacher et al., “Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 41, pp. 17111–17116, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Yildirim, Y. Ersoy, F. Ercan et al., “Phosphodiesterase-5 inhibition by sildenafil citrate in a rat model of bleomycin-induced lung fibrosis,” Pulmonary Pharmacology and Therapeutics, vol. 23, no. 3, pp. 215–221, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Zhao, L. Zhang, G. Lian et al., “Sildenafil attenuates LPS induced pro-inflammatory responses through downregulation of intracellular ROS-related MAPK/NF-kappaB signaling pathways in N9 microglia,” International Immunopharmacology, vol. 11, pp. 468–474, 2011. View at Google Scholar
  42. P. Pifarré, J. Prado, M. Giralt, A. Molinero, J. Hidalgo, and A. Garcia, “Cyclic GMP phosphodiesterase inhibition alters the glial inflammatory response, reduces oxidative stress and cell death and increases angiogenesis following focal brain injury,” Journal of Neurochemistry, vol. 112, no. 3, pp. 807–817, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. K. A. Kigerl, J. C. Gensel, D. P. Ankeny, J. K. Alexander, D. J. Donnelly, and P. G. Popovich, “Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord,” Journal of Neuroscience, vol. 29, no. 43, pp. 13435–13444, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. K. A. Kigerl, J. C. Gensel, D. P. Ankeny, J. K. Alexander, D. J. Donnelly, and P. G. Popovich, “Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord,” The Journal of Neuroscience, vol. 29, no. 43, pp. 13435–13444, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Raposo, A. K. D. S. Nunes, R. L. D. A. Luna, S. M. D. R. Araújo, M. A. Da Cruz-Höfling, and C. A. Peixoto, “Sildenafil (Viagra) protective effects on neuroinflammation: the role of iNOS/NO system in an inflammatory demyelination model,” Mediators of Inflammation, vol. 2013, Article ID 321460, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. B. D. Semple, T. Kossmann, and M. C. Morganti-Kossmann, “Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks,” Journal of Cerebral Blood Flow and Metabolism, vol. 30, no. 3, pp. 459–473, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. A. K. S. Nunes, C. Rapôso, W. H. de Oliveira et al., “Phosphodiesterase-5 inhibition promotes remyelination by MCP-1/CCR-2 and MMP-9 regulation in a cuprizone-induced demyelination model,” Experimental Neurology, vol. 275, pp. 143–153, 2016. View at Publisher · View at Google Scholar · View at Scopus
  48. N. Pizanis, J. Heckmann, D. Wendt, K. Tsagakis, H. Jakob, and M. Kamler, “Improvement of pulmonary microcirculation after lung transplantation using phosphodiesterase-5 inhibitor modified preservation solution,” European Journal of Cardio-thoracic Surgery, vol. 35, no. 5, pp. 801–806, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. M. H. Zahran, A. M. Hussein, N. Barakat et al., “Sildenafil activates antioxidant and antiapoptotic genes and inhibits proinflammatory cytokine genes in a rat model of renal ischemia/reperfusion injury,” International Urology and Nephrology, vol. 47, no. 11, pp. 1907–1915, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Jerzak, M. Kniotek, J. Mrozek, A. Górski, and W. Baranowski, “Sildenafil citrate decreased natural killer cell activity and enhanced chance of successful pregnancy in women with a history of recurrent miscarriage,” Fertility and Sterility, vol. 90, no. 5, pp. 1848–1853, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Ohams, M. Jerzak, and A. Górski, “Effects of sildenafil citrate and etanercept treatment on TNF-α levels in peripheral blood of women with recurrent miscarriage,” Ginekologia Polska, vol. 86, no. 7, pp. 520–524, 2015. View at Publisher · View at Google Scholar · View at Scopus
  52. M. El-Far, A. E.-G. El-Motwally, I. A. Hashem, and N. Bakry, “Biochemical role of intravaginal sildenafil citrate as a novel antiabortive agent in unexplained recurrent spontaneous miscarriage: first clinical study of four case reports from Egypt,” Clinical Chemistry and Laboratory Medicine, vol. 47, no. 11, pp. 1433–1438, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. J. A. Turner, “Diagnosis and management of pre-eclampsia: an update,” International Journal of Women's Health, vol. 2, no. 1, pp. 327–337, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. F. T. H. Wu, M. O. Stefanini, F. M. Gabhann, C. D. Kontos, B. H. Annex, and A. S. Popel, “A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use,” Journal of Cellular and Molecular Medicine, vol. 14, no. 3, pp. 528–552, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. L. Guedes-Martins, L. Matos, A. Soares, E. Silva, and H. Almeida, “AGEs, contributors to placental bed vascular changes leading to preeclampsia,” Free Radical Research, vol. 47, supplement 1, pp. 70–80, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. J. H. Jeong, H. G. Kim, and O. H. Choi, “Sildenafil inhibits advanced glycation end products-induced sFlt-1 release through upregulation of heme oxygenase-1,” Journal of Menopausal Medicine, vol. 20, no. 2, pp. 57–68, 2014. View at Publisher · View at Google Scholar
  57. M. Sarfati, V. Mateo, S. Baudet et al., “Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells,” Blood, vol. 101, no. 1, pp. 265–269, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. S. P. Treon, O. Tournilhac, A. R. Branagan et al., “Clinical responses to sildenafil in Waldenstrom's macroglobulinemia,” Clinical Lymphoma, vol. 5, no. 3, pp. 205–207, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. F. Gantner, C. Götz, V. Gekeler, C. Schudt, A. Wendel, and A. Hatzelmann, “Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation,” British Journal of Pharmacology, vol. 123, no. 6, pp. 1031–1038, 1998. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Fries, K. Shariat, H. Von Wilmowsky, and M. Böhm, “Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy,” Circulation, vol. 112, no. 19, pp. 2980–2985, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. T. Mostafa, “Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses,” Journal of Sexual Medicine, vol. 5, no. 11, pp. 2502–2518, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. A. B. Jaffe and A. Hall, “Rho GTPases: biochemistry and biology,” Annual Review of Cell and Developmental Biology, vol. 21, pp. 247–269, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. R.-G. Qiu, J. Chen, F. McCormick, and M. Symons, “A role for Rho in Ras transformation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 25, pp. 11781–11785, 1995. View at Publisher · View at Google Scholar · View at Scopus
  64. E. Sahai, M. F. Olson, and C. J. Marshall, “Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility,” EMBO Journal, vol. 20, no. 4, pp. 755–766, 2001. View at Publisher · View at Google Scholar · View at Scopus
  65. C. Guilluy, V. Sauzeau, M. Rolli-Derkinderen et al., “Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension,” British Journal of Pharmacology, vol. 146, no. 7, pp. 1010–1018, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. S. Caravita, M. B. Secchi, S. C. Wu, S. Pierini, and A. Paggi, “Sildenafil therapy for interferon-β-1a-induced pulmonary arterial hypertension: a case report,” Cardiology, vol. 120, no. 4, pp. 187–189, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. D. Santi, E. Giannetta, A. M. Isidori, C. Vitale, A. Aversa, and M. Simoni, “Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis,” European Journal of Endocrinology, vol. 172, no. 3, pp. R103–R114, 2015. View at Publisher · View at Google Scholar · View at Scopus
  68. A. Aversa, C. Vitale, M. Volterrani et al., “Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes,” Diabetic Medicine, vol. 25, no. 1, pp. 37–44, 2008. View at Publisher · View at Google Scholar · View at Scopus